title: A vaccine against HTLV-1 HBZ makes sense.
abstract: In this issue of Blood, Sugata et al report that vaccination against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could be used for immunotherapy in adult T-cell leukemia-lymphoma (ATL) patients.
authors: EQUIPE LABELISÉE LIGUE CONTRE LE CANCER, INSERM U1111-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UMR5308.
authors: Renaud
authors: R
authors: Mahieux
mesh_terms: D000818:Animals; D050976:Basic-Leucine Zipper Transcription Factors / Q000276:immunology*; D016356:Gene Products, tax / Q000276:immunology*; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000517:prevention & control*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology*
chemical_list: D050976:Basic-Leucine Zipper Transcription Factors; D016356:Gene Products, tax; D014614:Vaccines, Synthetic; D014764:Viral Proteins